Previous 10 | Next 10 |
Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel, Nov. 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that a...
TEL AVIV, Israel, Oct. 31, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...
Vascular Biogenics Ltd. (VBLT) Q2 2019 Earnings Conference Call August 13, 2019 8:30 AM ET Company Participants Michael Wood – LifeSci Advisors Dror Harats – Chief Executive Officer Amos Ron – Chief Financial Officer Conference Call Participants Kevin D...
VBL Therapeutics (NASDAQ: VBLT ): Q2 GAAP EPS of -$0.13 in-line. More news on: Vascular Biogenics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019, and provided a corporate update. “Our OVAL Phase 3 potential-registration trial of VB-111 in ovarian cancer continues as...
TEL AVIV, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...
TEL AVIV, Israel, July 22, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that its new gene therapy manufacturing facility i...
Thinly traded nano cap Vascular Biogenics ( VBLT +8.7% ) perks up on almost 20% higher volume, albeit on turnover of only 108K shares, on the heels of new coverage at Oppenheimer who rates it Outperform with a $2 (57% upside) price target. More news on: Vascular Biogenics Ltd., Healthcar...
The following slide deck was published by Vascular Biogenics Ltd. in conjunction with this Read more ...
TEL AVIV, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), announced that Dr. Dror Harats, CEO will deliver a company presentation today at the 2019 BIO International Convention in Philadelphia. The presentation will include a discussion on the rec...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...